Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nektar Therapeutics (NKTR) SEC filings page brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nektar’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market, and its filings provide structured insight into clinical progress, capital markets activity and corporate governance.
Recent Form 8-K reports include detailed descriptions of topline results from the Phase 2b REZOLVE-AD trial in atopic dermatitis and the Phase 2b REZOLVE-AA trial in alopecia areata, including study design, patient populations, primary and secondary endpoints, and summarized efficacy and safety outcomes. Other 8-K filings cover financial results for completed quarters, underwritten equity offerings under an effective shelf registration statement, and notices related to Nasdaq minimum bid price compliance.
Through these filings, investors can review how Nektar characterizes rezpegaldesleukin (REZPEG, or NKTR-358) as a first-in-class regulatory T cell stimulator and IL-2 pathway agonist, and how it describes additional pipeline programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. Filings also outline FDA Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as risk factor language and forward-looking statement disclaimers that frame development and regulatory uncertainty.
On Stock Titan, these SEC documents are updated as they are made available on EDGAR. AI-powered tools can help explain key sections of Nektar’s 8-Ks and related reports in plain language, highlight important clinical and financing disclosures, and surface items such as listing status updates and material agreements. This allows readers to quickly understand the implications of new filings for Nektar’s immunology pipeline and its Nasdaq-listed equity.
NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade. The weighted average sale price was $73.00 per share, and he held 21,174 shares directly after the transaction.
Nektar Therapeutics President & CEO Robin Howard W reported an open-market sale of 423 shares of common stock on February 18, 2026 at a weighted average price of $73.00 per share. According to the disclosure, these shares were sold to cover required tax withholding obligations related to vesting restricted stock units, and the filing notes this was not a discretionary trade. After the transaction, he directly held 75,489 shares of common stock, with an additional 28 shares held indirectly by his spouse.
Form 144 filing reports insider share sales and planned sales. The filing lists 423 common shares marked under "Securities To Be Sold" tied to Restricted Stock Vesting on
NKTR files a Section 144 notice to sell 180 common shares related to restricted stock vesting dated
The excerpt also records prior sales by Jonathan Zalevsky: 1,157 shares sold on
G1 Execution Services, Susquehanna Portfolio Strategies, and Susquehanna Securities filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 809,967 shares of Nektar Therapeutics common stock, equal to 4.0% of the class.
The filing is based on 20,341,589 shares outstanding as of November 10, 2025, as disclosed in the company’s Form S-3ASR. Susquehanna Securities’ position includes options to buy 410,600 shares. The firms state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Nektar.
Nektar Therapeutics is raising new capital through an upsized underwritten public offering of common stock and pre-funded warrants. The company agreed to sell 6,603,449 common shares at $58.00 each and 293,103 pre-funded warrants at $57.9999 each, with underwriters also exercising a 30-day option to buy an additional 1,034,482 common shares at the public price, all before underwriting discounts and commissions.
The transaction is expected to generate gross proceeds of about $400 million and is scheduled to close on February 13, 2026, subject to customary conditions. Nektar plans to use the net proceeds for general corporate purposes, including research and development, Phase 3 trials for rezpegaldesleukin, clinical development, and manufacturing costs to advance its drug pipeline.
Nektar Therapeutics is offering 6,603,449 shares of common stock and pre-funded warrants to purchase up to 293,103 shares, at $58.00 per share (or $57.9999 per pre-funded warrant), for estimated net proceeds of about $375.6 million, or $432.0 million if the underwriters fully exercise their option for 1,034,482 additional shares.
The company plans to use the cash, together with existing funds, for general corporate purposes, including research, clinical development and manufacturing, notably Phase 3 trials for its autoimmune drug candidate rezpegaldesleukin. Nektar reported preliminary cash and marketable securities of approximately $229.1 million as of January 31, 2026.
Recent Phase 2b REZOLVE‑AD data in atopic dermatitis showed sustained efficacy through 52 weeks and a well‑tolerated safety profile, and Nektar has aligned with the FDA on two Phase 3 registrational trials starting in the second quarter of 2026. The company highlights significant dilution to new investors versus its September 30, 2025 net tangible book value per share.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.
The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.
Nektar Therapeutics reported new 36-week maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Among re-randomized responders, both monthly (Q4W) and quarterly (Q12W) dosing maintained high response rates, including up to 83% maintaining EASI-75 and strong vIGA-AD and itch responses.
A meaningful share of patients also achieved new or deeper responses by Week 52, including increases in EASI-90 and EASI-100 rates, indicating continued improvement with longer treatment. The safety profile over 52 weeks remained consistent with induction, with low discontinuations, mainly mild injection site reactions, and no new safety concerns.
Nektar held an End of Phase 2 meeting with the FDA and reached alignment on a 24 µg/kg Q2W induction dose and co-primary endpoints for two planned Phase 3 registrational trials, which will include a 36-week maintenance period with Q4W and Q12W regimens. The company plans to start Phase 3 in the second quarter of 2026 and is targeting a BLA filing in 2029 based on its broader development plan.